1. Home
  2. FRPT vs CORT Comparison

FRPT vs CORT Comparison

Compare FRPT & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshpet Inc.

FRPT

Freshpet Inc.

HOLD

Current Price

$73.04

Market Cap

2.7B

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

N/A

Current Price

$114.23

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRPT
CORT
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
9.7B
IPO Year
2014
2001

Fundamental Metrics

Financial Performance
Metric
FRPT
CORT
Price
$73.04
$114.23
Analyst Decision
Buy
Buy
Analyst Count
17
5
Target Price
$76.94
$96.50
AVG Volume (30 Days)
1.4M
1.2M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
183.87
N/A
EPS
1.29
0.09
Revenue
$1,102,015,000.00
$761,407,000.00
Revenue This Year
$11.34
$26.08
Revenue Next Year
$9.13
$26.98
P/E Ratio
$56.38
$1,228.89
Revenue Growth
13.01
12.79
52 Week Low
$46.45
$28.66
52 Week High
$86.00
$122.21

Technical Indicators

Market Signals
Indicator
FRPT
CORT
Relative Strength Index (RSI) 71.50 64.64
Support Level $64.96 $76.41
Resistance Level $86.00 $122.21
Average True Range (ATR) 3.25 5.13
MACD 1.00 -0.09
Stochastic Oscillator 94.90 75.23

Price Performance

Historical Comparison
FRPT
CORT

About FRPT Freshpet Inc.

Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (likely representing well north of 90% of sales), with cats and treats nascent contributors. Geographically, the company's home US market, where all its food is produced, accounts for nearly all of sales, with exports to Canada, the United Kingdom, and other European countries being very small contributors.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: